✦ LIBER ✦

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

✍ Scribed by Harter, Philipp; Sehouli, Jalid; Kimmig, Rainer; Rau, JÃ¶rn; Hilpert, Felix; Kurzeder, Christian; Elser, Gabriele; Bois, Andreas

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib in combination with tamoxifen

✍ Uwe Wagner; Andreas du Bois; Jacobus Pfisterer; Jens Huober; Sybille Loibl; Hans 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Efficacy of pegylated liposomal doxorubi

✍ Patti Power; Gavin Stuart; Amit Oza; D. Provencher; James R. Bentley; Wilson H. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 395 KB

Impact of age on outcome in patients wit

✍ Pauline Wimberger; Nils Lehmann; Rainer Kimmig; Alexander Burges; Werner Meier; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 226 KB

Combination therapy with pegylated lipos

✍ A. du Bois; J. Pfisterer; N. Burchardi; S. Loibl; J. Huober; P. Wimberger; A. Bu 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 302 KB

172 Phase I/II study of PLD and carbopla

✍ V. Heilmann; A. Burges; M. Gropp; J. Pfisterer; B. Schmalfeldt; B. Richter; Ch. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 164 KB

A randomized phase II study of carboplat

✍ Dimitrios Bafaloukos; Helena Linardou; Gerasimos Aravantinos; Christos Papadimit 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 332 KB